• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者偏好研究在医疗保健决策中不断演变的作用,从临床药物研发到临床护理管理。

The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management.

作者信息

Jackson Yanina, Janssen Ellen, Fischer Ryan, Beaverson Katherine, Loftus Jane, Betteridge Kate, Rhoten Stephanie, Flood Emuella, Lundie Mark

机构信息

a Pfizer Inc , New York, NY, USA.

b ICON plc , Gaithersburg, MD, USA.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):383-396. doi: 10.1080/14737167.2019.1612242. Epub 2019 May 9.

DOI:10.1080/14737167.2019.1612242
PMID:31070048
Abstract

: There is a growing trend of using patient preference studies to help incorporate the patient perspective into clinical drug development, care management, and health-care decision-making. Collecting and interpreting patient preference data is integral to multi-stakeholder engagement, patient-centric drug development, and clinical care management. Operationally, challenges exist in understanding 'when' and 'how' to embark on patient preference studies. This review will provide a brief overview of stated-preference methods, discuss applications throughout the clinical drug development and care management, and highlight how preference studies serve as a powerful tool for quantifying patient experiences for better outcomes. : We present case studies to complement the different applications of stated-preference methods in clinical drug development and care management. We discuss the applications of preference data to help inform evidence-based patient advocacy, clinical development strategy, operational feasibility, regulator benefit-risk assessments, health technology assessments, and clinical decision-making. : Patient preference studies can serve as a powerful tool to engage patients and their communities as well as quantify the patient voice across different stages of clinical drug development and care management to support patient-centric health-care decision-making. It is expected that the application of these strategies will quickly advance in the coming years.

摘要

使用患者偏好研究以将患者观点纳入临床药物开发、护理管理和医疗保健决策的趋势日益增长。收集和解读患者偏好数据对于多利益相关方参与、以患者为中心的药物开发及临床护理管理而言不可或缺。在实际操作中,在理解“何时”以及“如何”开展患者偏好研究方面存在挑战。本综述将简要概述陈述性偏好方法,讨论其在整个临床药物开发和护理管理中的应用,并强调偏好研究如何作为一种强大工具来量化患者体验以实现更好的结果。:我们展示案例研究以补充陈述性偏好方法在临床药物开发和护理管理中的不同应用。我们讨论偏好数据的应用,以帮助为循证患者支持、临床开发策略、操作可行性、监管机构的获益-风险评估、卫生技术评估及临床决策提供信息。:患者偏好研究可作为一种强大工具,让患者及其社区参与进来,并在临床药物开发和护理管理的不同阶段量化患者声音,以支持以患者为中心的医疗保健决策。预计这些策略的应用在未来几年将迅速发展。

相似文献

1
The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management.患者偏好研究在医疗保健决策中不断演变的作用,从临床药物研发到临床护理管理。
Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):383-396. doi: 10.1080/14737167.2019.1612242. Epub 2019 May 9.
2
Patient-centric HTA: different strokes for different folks.以患者为中心的卫生技术评估:因人而异。
Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):591-7. doi: 10.1586/14737167.2015.1038245. Epub 2015 Apr 20.
3
Quantifying Preferences in Drug Benefit-Risk Decisions.量化药物获益-风险决策中的偏好。
Clin Pharmacol Ther. 2019 Nov;106(5):955-959. doi: 10.1002/cpt.1447. Epub 2019 Apr 24.
4
Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy.在医疗保健决策中应征求谁的偏好?一项使用抗凝治疗的案例研究。
Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):33-9. doi: 10.1586/14737167.2016.1115722. Epub 2015 Nov 20.
5
The evolution of patient-focused drug development and Duchenne muscular dystrophy.以患者为中心的药物研发与杜氏肌营养不良症的发展。
Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):57-68. doi: 10.1080/14737167.2020.1734454. Epub 2020 Mar 6.
6
Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.开展获益-风险患者偏好研究中的有效合作:来自患者权益倡导组织、制药公司和学术陈述偏好研究者的观点。
Ther Innov Regul Sci. 2018 Jul;52(4):507-513. doi: 10.1177/2168479017746404. Epub 2017 Dec 13.
7
PATIENT-CENTERED DECISION MAKING: LESSONS FROM MULTI-CRITERIA DECISION ANALYSIS FOR QUANTIFYING PATIENT PREFERENCES.以患者为中心的决策制定:通过多准则决策分析量化患者偏好的经验教训。
Int J Technol Assess Health Care. 2018 Jan;34(1):105-110. doi: 10.1017/S0266462317001118. Epub 2017 Dec 26.
8
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.欧洲健康偏好研究:在药品营销许可、报销和定价决策中的应用综述——ISPOR 偏好研究特别兴趣小组报告。
Value Health. 2020 Jul;23(7):831-841. doi: 10.1016/j.jval.2019.11.009. Epub 2020 Jul 5.
9
Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?提高健康领域离散选择实验的质量:我们如何评估有效性和可靠性?
Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):531-542. doi: 10.1080/14737167.2017.1389648. Epub 2017 Oct 23.
10
Eliciting Preferences in Dentistry with Multiattribute Stated Preference Methods: A Systematic Review.使用多属性陈述偏好方法在牙科领域引出偏好:一项系统评价。
JDR Clin Trans Res. 2018 Oct;3(4):326-335. doi: 10.1177/2380084418780324. Epub 2018 Jun 1.

引用本文的文献

1
Subcutaneous Infusion of Benzathine Penicillin G Is Acceptable and Preferred Over Intramuscular Injections for Syphilis in Western Australian Sexual Health Clinic Attendees: A Mixed Methods Sub-study.在西澳大利亚性健康诊所就诊者中,苄星青霉素G皮下输注治疗梅毒是可接受的,且优于肌内注射:一项混合方法子研究。
Patient. 2025 Aug 22. doi: 10.1007/s40271-025-00764-4.
2
Global research on patient involvement in health technology assessment: a bibliometric analysis.全球关于患者参与卫生技术评估的研究:一项文献计量分析。
Glob Health Res Policy. 2025 Jul 25;10(1):30. doi: 10.1186/s41256-025-00431-z.
3
Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials in Drug Development From a Multi-Stakeholder Perspective: A Scoping Review.
从多利益相关方角度看药物研发中启动后期临床试验的决策标准与方法:一项范围综述
Clin Pharmacol Ther. 2025 Apr;117(4):978-988. doi: 10.1002/cpt.3566. Epub 2025 Feb 19.
4
Using Adaptive Choice-Based Conjoint Approach to Facilitate Shared Decision-Making in Osteoarthritis Management: A Patient Perception Study.运用基于适应性选择的联合分析方法促进骨关节炎管理中的共同决策:一项患者认知研究。
Arthritis Care Res (Hoboken). 2025 Feb;77(2):240-250. doi: 10.1002/acr.25429. Epub 2024 Oct 17.
5
Factors influencing patient experience in hospital wards: a systematic review.影响医院病房患者体验的因素:一项系统综述。
BMC Nurs. 2024 Aug 1;23(1):527. doi: 10.1186/s12912-024-02054-0.
6
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri) Dosing: NOVA Phase IIIb Extension Study (Part 2).每6周注射那他珠单抗(泰萨比)时患者对皮下注射与静脉注射给药方式的偏好:NOVA IIIb期扩展研究(第2部分)
Neurol Ther. 2024 Oct;13(5):1385-1401. doi: 10.1007/s40120-024-00647-0. Epub 2024 Jul 24.
7
Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment.加拿大成年人对预防性偏头痛治疗的偏好:一项离散选择实验。
Headache. 2025 Jan;65(1):113-123. doi: 10.1111/head.14781. Epub 2024 Jul 9.
8
Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma.探索生物疗法的认知:加拿大严重哮喘患者定性研究。
Adv Ther. 2024 Apr;41(4):1401-1418. doi: 10.1007/s12325-024-02803-2. Epub 2024 Feb 13.
9
Development and validation of the patient-reported outcome scale for chronic kidney disease.慢性肾脏病患者报告结局量表的制定与验证。
Int Urol Nephrol. 2024 Feb;56(2):653-665. doi: 10.1007/s11255-023-03702-1. Epub 2023 Jul 15.
10
Patient Preferences for Cardiac Rehabilitation - A Systematic Review.心脏康复的患者偏好——一项系统评价
Patient Prefer Adherence. 2023 Jan 6;17:75-88. doi: 10.2147/PPA.S392417. eCollection 2023.